Folic acid functionalized nanoparticles as pharmaceutical carriers in drug delivery systems

Drug Dev Res. 2019 Jun;80(4):404-424. doi: 10.1002/ddr.21545. Epub 2019 May 29.

Abstract

Conventional chemotherapeutic approaches in cancer therapy such as surgery, chemotherapy, and radiotherapy have several disadvantages due to their nontargeted distributions in the whole body. On the other hand, nanoparticles (NPs) based therapies are remarkably progressing to solve several limitations of conventional drug delivery systems (DDSs) including nonspecific biodistribution and targeting, poor water solubility, weak bioavailability and biodegradability, low pharmacokinetic properties, and so forth. The enhanced permeability and retention effect escape from P-glycoprotein trap in cancer cells as a passive targeting mechanism, and active targeting strategies are also other most important advantages of NPs in cancer diagnosis and therapy. Folic acid (FA) is one of the biologic molecules which has been targeted overexpressed-folic acid receptor (FR) on the surface of cancer cells. Therefore, conjugation of FA to NPs most easily enhances the FR-mediated targeting delivery of therapeutic agents. Here, the recent works in FA which have been decorated NPs-based DDSs are discussed and cancer therapy potency of these NPs in clinical trials are presented.

Keywords: cancer diagnosis and therapy; folic acid; nanoparticles; nanotechnology; targeted drug delivery.

Publication types

  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents / administration & dosage*
  • Cell Line, Tumor
  • Drug Carriers / chemistry*
  • Drug Delivery Systems
  • Drug Evaluation, Preclinical
  • Folic Acid / chemistry*
  • Humans
  • Nanoparticles / chemistry*
  • Neoplasms / drug therapy
  • Neoplasms / pathology

Substances

  • Antineoplastic Agents
  • Drug Carriers
  • Folic Acid